TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with T1DM on regular insulin therapy.~* age from 12 to 18 years.~* disease duration at least 5 years.~* having diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[UAE\] 30-299 mg/g creatinine).~* hemoglobin A1c (HbA1c) ≤8.5% (69 mmol/mol).~* persistent microalbuminuria was confirmed by abnormal two or three urine samples over a 3- to 6-months period prior to the study despite angiotensin converting enzyme inhibitors (ACE-Is)~Exclusion Criteria:~* patients with any clinical evidence of infection.~* patients with renal impairment due to causes other than diabetes.~* other diabetic complications than nephropathy.~* elevated liver enzymes.~* hyper- or hypo-thyroidism.~* intake of any vitamins or food supplements one month before study.~* participation in a previous investigational drug study within the three months preceding screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- oral omega-3 fatty acids supplementation (Type: ACTIVE_COMPARATOR): Intervention group included pediatric patients with diabetic nephropathy receiving oral omega-3 fatty acids supplementation on a daily basis.
- Placebo comparator (Type: PLACEBO_COMPARATOR): Placebo group or control patients received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of the Active Straight Leg Raise on the Efficacy of a SJB in Posterior PGP During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking pregnant women presenting in their second or third trimester with posterior PGP. Trimester will be determined from date of last menses or ultrasound date.~* Pain must be between the upper level of the iliac crests and the gluteal folds in conjunction with or separately from pain in the pubic symphysis and influenced by position and locomotion~* ASLR score between 2-10~Exclusion Criteria:~* Non-English speaking pregnant women \<18 or \>50 years old~* Women presenting with PGP in the first trimester (\<13 weeks gestation)~* Women with pubic symphysis (anterior) pain alone~* Pain above the upper level of the iliac crest~* ASLR total score of \<2~* History of lumbar or pelvic fracture, neoplasm, inflammatory disease, active urogenital infection or active gastrointestinal illness, previous surgery of the lumbar spine, pelvic girdle, hip joint or femur~* History or signs of radiculopathy or other systemic neurologic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Sacroiliac Joint Belt (Type: OTHER): All patients will receive and be fitted by the PI with an SIJ belt.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients after a major abdominal surgery~* Written informed consent obtained~Exclusion Criteria:~* Subject has history of symptomatic deep vein thrombosis and/or pulmonary embolism~* Subject has a hemorrhagic disorder and/or coagulation disorder~* Subject has had clinically important bleeding occurred within 90 days prior to the screening visit~* Subject has an active bacterial endocarditis~* Subject has uncontrolled severe or moderate hypertension, retinopathy, myocardial infarction or stroke~* Subject is receiving anticoagulants/antiplatelet agents~* Subject has a thrombocytopenia~* Body weight less than 40 kg at the screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YM150 group (Type: EXPERIMENTAL): None
- mechanical prophylaxis group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis B, HBe antigen negative~* treatment with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detection in conventional HBV-PCR assays, i.e. \<116 IU / ml).~* 18-70 ys~* willingness and ability to give informed consent and to follow study procedures~* willingness to use adequate contraception~Exclusion Criteria:~* contraindications against treatment with pegylated interferon, e.g. depression, uncontrolled epilepsy, autoimmune diseases, pregnancy, leukocytopenia or thrombocytopenia at screening, etc.~* active alcohol or drug abuse~* preexisting polyneuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
- Control group (Type: NO_INTERVENTION): ongoing nucleos(t)ide based treatment alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefit of a Single Preoperative Dose of Antibiotics for the Prevention of Surgical Site Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* surgical patient~* clean or clean-contaminated surgery~Exclusion Criteria:~* infection~* preoperative antibiotic treatment~* postoperative antibiotic treatment~* open fractures

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abx (Type: EXPERIMENTAL): single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* • The patient is a man or woman aged ≥65 yrs~  * The patient has Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™).~ * The patient has an inadequate response to at least one adequate antidepressant treatment in the current Major Depressive Episode (MDE).~ * The patient has had the current MDE for ≥8 weeks~ * The patient is currently treated with a protocol specified ADT for at least 6 weeks~ * The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator.~ * Montgomery and Åsberg Depression Rating Scale (MADRS) total score \> 18 at screening and baseline~ * Clinical Global Impression - Severity (CGI-S) total score ≥3 at screening and baseline~Main Exclusion Criteria:~* • The patient has a clinically significant unstable illness~  * The patient has newly diagnosed or unstable diabetes~ * The patient has a Mini Mental State Exam (MMSE) score \<24~ * The patient has received Transcranial Magnetic Stimulation (TMS) and/or electroconvulsive therapy (ECT) less than 6 months prior to the Screening.~ * The patient, in the opinion of the investigator or based on Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation and behaviour rating, is at significant risk of suicide~Other protocol defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjunct brexpiprazole (Type: EXPERIMENTAL): All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* biopsy proved nasopharyngeal carcinoma;~* stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;~* 18 years or older; without other malignancy;~* proper functioning of the major organs.~Exclusion Criteria:~* allergic to anlotinib;~* female within gestation period or lactation;~* patients received drug of other clinical trial within 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 6 years~* Able to provide written informed consent~* Clinical diagnosis of CPVT~* Able to exercise on a treadmill~* Successful completion of a minimum of 2 exercise stress tests without adverse events~Exclusion Criteria:~* Contraindication to treadmill stress testing according to Vanderbilt University Medical Center's clinical protocols (unstable angina, decompensated congestive heart failure, severe hypertension (≥ 170/90 mmHg), acute myocardial infarction (\<4 days), moderate to severe aortic stenosis, acute pulmonary embolism, severe pulmonary hypertension, outflow tract obstruction, hypertrophic cardiomyopathy, left main coronary stenosis, left bundle branch block)~* Females who are pregnant~* In the judgement of the investigator, any clinically significant ongoing medical or surgical condition that might jeopardize the subject's safety or interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treadmill then Treadmill with Atropine (Type: EXPERIMENTAL): Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject ≥ 9 years of age.~* Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhidrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4 and (c) a minimum GSP of 50 mg in each axilla with a combined total of at least 150 mg.~* The ability to understand and follow all study-related procedures including study drug administration.~* Sexually active female of childbearing potential (FOCBP)\* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.~Exclusion Criteria:~* In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(e).~* Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.~* Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by any route of administration.~* Use of any cholinergic drug (e.g. bethanechol) within 28 days.~* Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism, diabetes mellitus, medications, etc.).~* Subjects with unstable diabetes mellitus or thyroid disease, history of renal or hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions, Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate sweat production by the use of anticholinergics in the investigator's opinion.~* Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation.~* Subject is pregnant, lactating or is planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Sofpironium bromide, 15% gel, once per day
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle gel, once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of an Antioxidants Mix on Cognitive Performance and Well Being: The Bacopa, Licopene, Astaxantina, Vitamin B12

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged ≥60 years.~2. Subjects who provide written Informed Consent to the study.~Exclusion Criteria:~1. Subjects with cognitive dysfunctions or clinically significant coexisting medical conditions (cardiovascular disease, cerebrovascular events, overt dementia defined by MMSE \<27 or other neurological disorders, thyroid disorders, or inflammatory diseases)~2. Subjects with a score on the Geriatric Depression Scale (GDS) \>11 in order to avoid confounding due to the influence of concomitant depression on the performance on cognitive tests~3. Current smokers~4. Habitual users of antioxidant supplements (including vitamins C and E)~5. Habitual consumers of chocolate or other cocoa products (daily consumption of any amount)~6. Subjects under treatments with medications known to have antioxidant properties (including statins and glitazones) or to interfere with cognitive functions (including benzodiazepines and antidepressants)~7. Subjects with hypersensitivity to any component of the study medications~8. Subjects who are participating in or having participated in another clinical trial within the previous three months.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Food supplement (Type: EXPERIMENTAL): A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Statin/Vitamin D & Migraine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Have had migraines for at least 3 years~* Have between 4 and 15 migraines a month~* Able to speak and read the English language~Exclusion Criteria:~* Women who are pregnant or nursing, or planning on becoming pregnant in the next 10 months~* Individuals who have a had a heart attack, stroke, peripheral artery disease, atherosclerotic aortic disease, carotid artery disease, or diabetes~* individuals at high risk for cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin and vitamin D (Type: EXPERIMENTAL): Participants in this arm will receive simvastatin + vitamin D.
- Placebo Sugar Pill (Type: PLACEBO_COMPARATOR): Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female subjects, who have signed the informed consent form must meet all of the following criteria~  1. 18 to 45 years of age~ 2. Body mass index (BMI) \> 19 and \< 0 kg/m2~ 3. Normal ECG, vital signs and laboratory test results~ 4. Use of effective birth control method and abstinence from sex~ 5. Negative pregnancy test and drug screen~Exclusion Criteria:~* Subjects with any of the following characteristics will be considered ineligible:~  1. History of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological, immunological, neurologic or psychiatric disorders or connective tissue disease~ 2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen (HBsAg) or Hepatitis C antibody, tuberculosis (TB)~ 3. Current drug or alcohol addiction~ 4. History of clinically significant allergy of any kind~ 5. Prior use of IL-12 or HemaMax~ 6. Use of any approved or investigational biologic agents or vaccinations of any kind in last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HemaMax (Type: EXPERIMENTAL): Single subcutaneous 12 microgram dose of HemaMax
- Placebo (Type: PLACEBO_COMPARATOR): Single subcutaneous dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Depressed Mood Improvement Through Nicotine Dosing 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 60 years;~2. Diagnosis of major depressive disorder, single or recurrent episode (DSM5);~3. On a stable therapeutic dose of an allowed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for at least 8 weeks;~4. Severity: Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 15;~5. Cognition: Mini-Mental State Examination (MMSE) score ≥ 24;~6. Fluent in English~Exclusion Criteria:~1. Other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring in a depressive episode;~2. Use of other medications for depression, e.g., bupropion or augmenting agents, although short-acting sedatives are allowed (see below);~3. Any use of tobacco or nicotine in the last year;~4. Living with a smoker or regular exposure to secondhand smoke;~5. History of alcohol use disorder or substance use disorder of moderate or greater severity (endorsing 4 or more of the 12 criteria) in the last 12 months;~6. Acute suicidality;~7. Acute grief (\<1 month);~8. Current or past psychosis;~9. Primary neurological disorder, including dementia, stroke, epilepsy, etc.;~10. MRI contraindication;~11. Electroconvulsive therapy or transcranial magnetic stimulation in last 2 months;~12. Current or planned psychotherapy;~13. Allergy or hypersensitivity to nicotine patches;~14. In the last 4 weeks, regular use of drugs with central cholinergic or anticholinergic properties or moderate / severe CYP2A6 inhibitors /inducers.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal Nicotine Patch (Type: EXPERIMENTAL): Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete